1. Highlights of Prescribing Information Dasatinib [Internet]. Maryland: food and drug administration; 2017[Reference ID: 4350141:[Available from:https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021986s7s8lbl.pdf.
2. LaCivita C., Dempsey M.Risk assessment and risk mitigation review of ponatinib. 2012. [Internet]. Department of Health and Human Services. Public Health Service, Food and Drug Administration, Center for Drug Evaluation and Research Office of Surveillance and Epidemiology, Office of Medication Error Prevention and Risk Management; 2012[Reference ID: 3222501:[Available from: https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=2ahUKEwiAiuiYxcnkAhUyuVkKHbklBXgQFjAAegQIABAC&url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Fnda%2F2012%2F203469Orig1s000RiskR.pdf&usg=AOvVaw108_-L5E2ZxgRZzdaUhyDl.
3. Acute renal failure under dasatinib therapy;Ozkurt;Ren Fail.,2010
4. Dasatinib-induced nephrotic-range proteinuria;Wallace;Am. J. Kidney Dis.,2013
5. Dasatinib in chronic myeloid leukemia: a review;Aguilera;Ther. Clin. Risk Manag.,2009